Highest-materiality recent filing
Vericel amends bylaws to update address following headquarters move
Board approved amendment effective May 18, 2026.
Vericel Q1 revenue up 30% to $68.4M, net loss narrows; raises FY revenue guidance to $326-336M
Total revenue up 30% to $68.4M; MACI revenue up 22% to $56.4M, Burn Care up 91% to $12.0M.
Vericel shareholders elect all seven director nominees, approve say-on-pay and auditor ratification
All seven director nominees elected with votes ranging from 38.3M to 45.2M for; highest withhold 7.8M for Heidi Hagen.
Vericel Q4 2025 total revenue $92.9M (+23% YoY); FY25 net income up 59% to $16.5M
Q4 total revenue $92.9M (+23% YoY); MACI revenue $84.1M (+23%); burn care $8.8M.
Vericel prelim 2025 revenue $276M (+23% Q4); MACI rev $239.5M; GAAP net profitable 2nd year
Total revenue ~$276M; MACI $239.5M (+20%+ YoY 3rd consecutive yr); Burn Care $36.5M.
Vericel reports record Q3 revenue $67.5M; net income $5.1M vs loss
Total revenue $67.5M (record Q3), MACI $55.7M (+25% YoY), Burn Care $11.8M (Epicel $10.4M, NexoBrid $1.5M).
Vericel Q2 revenue $63.2M (+20% YoY); net loss narrows to $0.6M; adj. EBITDA up 112% to $13.4M
Record Q2 total revenue $63.2M, up 20% YoY; MACI revenue $53.5M, up 21%.
Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance
Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.
Vericel shareholders approve 5.09M share increase in 2022 Omnibus Incentive Plan and 2M share ESPP
Shareholders approved 5,088,095 share increase under Amended and Restated 2022 Omnibus Incentive Plan.
Vericel sees negligible impact from U.S. tariffs on COGS and gross margin
All operations in U.S.; 100% of 2025 revenue from domestic sales.
Vericel reports record Q4 gross margin 78%, FY2024 revenue up 20% to $237M, net income positive
Full-year 2024 revenue $237.2M (+20% YoY); MACI $197.3M (+20%), Burn Care $39.9M (+22%).
FY2024 total revenue ~$237-237.5M (+20% YoY); MACI revenue ~$197.2-197.7M (+20%); Burn Care $40M (+22%).
Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance
Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).
FDA approves Vericel's MACI Arthro for arthroscopic knee cartilage repair
FDA approved sBLA for arthroscopic delivery of MACI (MACI Arthro) to repair knee defects up to 4 cm².
Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment
FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.
Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%
MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.
Vericel Q1 revenue up 25% to $51.3M; raises FY2024 guidance to $238-242M
MACI revenue grew 18% to $40.2M; Burn Care revenue up 63% to $11.1M (Epicel $10.7M, NexoBrid $0.4M).
All eight director nominees elected with 35.2M to 42.3M votes each; Robert Zerbe received 41.3M for.
Vericel reports FY2023 revenue $197.5M (+20% YoY); Q4 revenue $65.0M; FY2024 guidance $237-241M
Q4 net income $13.0M ($0.26 diluted EPS) vs $5.9M in Q4 2022, up 119%.
Vericel reports preliminary FY2023 revenue ~$197.5M (+20% YoY); Q4 revenue $65M (+23%)
FY2023 preliminary total revenue ~$197.5M (+20% YoY); MACI revenue ~$164.8M (+25%); Burn Care revenue ~$32.7M.
Vericel reports Q3 2023 revenue of $45.6M (+18% YoY), raises FY guidance
Total revenue $45.6M (+18% YoY); MACI revenue $37.6M (+21% YoY).
Vericel launches NexoBrid in U.S. for severe thermal burns; $300M addressable market
Full commercial launch of NexoBrid for eschar removal in adults with deep partial/full-thickness thermal burns.
Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M
Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).
Vericel reports record Q1 2023 revenue of $41M; MACI up 32%; raises full-year guidance
Q1 total revenue $41.0M (+14% YoY); MACI revenue $34.2M (+32% YoY); Epicel $6.8M.
Vericel adopts deferred comp plan; shareholders reelect directors at annual meeting
Board adopted Vericel Corporation Deferred Compensation Plan effective May 3, 2023.
Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M
Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.
Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved
Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.
Vericel gets FDA approval for NexoBrid to treat severe thermal burns in adults
FDA approved NexoBrid (anacaulase-bcdb) for eschar removal in adults with deep partial- and full-thickness thermal burns.
Vericel Q3 revenue $38.6M (+12% YoY); MACI $31M (+30%); net loss $6.6M; FY22 guidance $164-166M
Total net revenue $38.6M (+12% YoY); MACI net revenue $31.0M (+30% YoY); Epicel $7.3M; NexoBrid $0.2M.
Total net revenue $37.0M (MACI $28.6M +8% YoY, Epicel $8.2M, NexoBrid $0.2M); net loss $9.0M ($0.19/sh).
Vericel enters $150M senior secured revolving credit facility due 2027
$150 million five-year senior secured revolver; matures July 29, 2027.
Vericel Q1 revenue up 4% to $36.1M; net loss widens to $7.1M; reaffirms FY2022 guidance
Total net revenue $36.1M (+4% YoY); MACI $26.0M, Epicel $9.9M, NexoBrid $0.2M.
Vericel shareholders approve 2022 Omnibus Incentive Plan, re-elect all directors
Elected 8 directors: Zerbe, Rubino, Hagen, Gilman, McLaughlin, Wotton, Wright, Colangelo (each >35M votes for).
Vericel appoints Jonathan Siegal as Principal Accounting Officer effective Feb 16
Jonathan Siegal, VP and Corporate Controller, appointed principal accounting officer effective Feb 16, 2022.
Vericel FY2021 revenue $156.2M (+26% YoY); net loss $7.5M; guides FY2022 revenue $178-189M
FY2021 total net revenue $156.2M (up 26% YoY); MACI $111.6M, Epicel $41.5M.
Vericel signs 125,749 sq ft lease for Burlington, MA HQ and manufacturing facility
Signed 144-month lease with one 120-month extension option for to-be-constructed manufacturing, lab, and office space.
Vericel estimates FY2021 revenue growth 25-26%, adj. EBITDA ~$30M, cash ~$129M
Preliminary FY2021 revenue growth of 25%-26% (unaudited); total adjusted EBITDA ~$30M.
Vericel Q3 revenue up 7% to $34.5M; guides FY2021 revenue $158-$161M
Q3 total net revenue $34.5M (+7% YoY); MACI $23.9M, Epicel $9.8M (+48% YoY).
Vericel enters ATM equity offering agreement for up to $200M
Agreement with SVB Leerink LLC to sell up to $200M of common stock in at-the-market offerings.
Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M
Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.
On February 16, 2022, Jonathan Siegal, Vericel Corporation’s (the “Company”) Vice President and Corporate Controller was appointed principal accounting officer, effective immediately.
Mr. Siegal replaces Joseph Mara who was acting as the Company’s principal accounting officer.
Max materiality 0.85 · Median 0.75 · Most common event earnings